Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26796
Abstract: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. read more here.
Keywords: waldenstr macroglobulinemia; macroglobulinemia 2023; update diagnosis; waldenstr ... See more keywords
Waldenström's macroglobulinemia masquerading as ovarian cancer with peritoneal carcinomatosis, ascites, and elevated CA-125.
Sign Up to like & getrecommendations! Published in 2019 at "Hematology/oncology and stem cell therapy"
DOI: 10.1016/j.hemonc.2017.02.004
Abstract: Waldenström's macroglobulinemia is a rare hematology malignancy which often presents with "B symptoms," anemia, and thrombocytopenia. A 46-year-old woman presented with 2 months of abdominal distension accompanied by an unintentional 20-lb weight loss. Her abdominal… read more here.
Keywords: waldenstr macroglobulinemia; waldenstr; hematology; carcinomatosis ... See more keywords
Familial Waldenström Macroglobulinemia: Families Informing Populations.
Sign Up to like & getrecommendations! Published in 2018 at "Hematology/oncology clinics of North America"
DOI: 10.1016/j.hoc.2018.05.006
Abstract: Familial clustering of Waldenström macroglobulinemia (WM) has been observed for nearly 6 decades. Family studies have provided seminal observations in delineating the phenotypic spectrum of WM susceptibility and confirming the importance of immunoglobulin M (IgM)… read more here.
Keywords: waldenstr macroglobulinemia; waldenstr; familial waldenstr; macroglobulinemia families ... See more keywords
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia.
Sign Up to like & getrecommendations! Published in 2023 at "Seminars in hematology"
DOI: 10.1053/j.seminhematol.2023.03.007
Abstract: Apart from the MYD88L265P mutation, extensive information exists on the molecular mechanisms in Waldenström's Macroglobulinemia and its potential utility in the diagnosis and treatment tailoring. However, no consensus recommendations are yet available. Consensus Panel 3… read more here.
Keywords: consensus panel; waldenstr macroglobulinemia; waldenstr; diagnosis ... See more keywords
Dose of ibrutinib in Waldenström macroglobulinaemia: Less can be more
Sign Up to like & getrecommendations! Published in 2023 at "British Journal of Haematology"
DOI: 10.1111/bjh.18664
Abstract: Ibrutinib changed the landscape of treatment in Waldenström macroglobulinaemia (WM) with excellent responses; however, there are high rates of dose reduction due to adverse events. The impact of this reduced dosing is unclear with regards… read more here.
Keywords: macroglobulinaemia less; dose ibrutinib; ibrutinib waldenstr; waldenstr macroglobulinaemia ... See more keywords
A fatal disseminated cryptococcal infection in a patient treated with zanubrutinib for Waldenström’s macroglobulinemia
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552221087730
Abstract: Introduction Zanubrutinib is a second generation, irreversible small-molecule Bruton tyrosine kinase inhibitor (BTK) approved for the treatment of Waldenström's macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma. As a class, BTKs have been linked with… read more here.
Keywords: waldenstr macroglobulinemia; cryptococcal infection; disseminated cryptococcal; patient ... See more keywords